Organic compounds -- part of the class 532-570 series – Organic compounds – Four or more ring nitrogens in the bicyclo ring system
Reexamination Certificate
2006-06-27
2006-06-27
McKenzie, Thomas C. (Department: 1624)
Organic compounds -- part of the class 532-570 series
Organic compounds
Four or more ring nitrogens in the bicyclo ring system
Reexamination Certificate
active
07067657
ABSTRACT:
Provided herein is a compound having the formula (Ia):wherein said compounds are useful for the treatment or prophylaxis of neurodegenerative disorders, demyelinating disease and pain.
REFERENCES:
patent: 0009511 (2000-02-01), None
patent: 0158907 (2001-08-01), None
Umehara H, Bloom ET, Okazaki T, Nagano Y, Yoshie O, Imai T, Arterioscler Thromb Vasc Biol. Jan. 2004; 24(1):34-40, Epub Sep. 11, 2003.
Zujovic et al., “Fractalkine Modulates TNF-alpha Secretion and Neurotoxicity Induced by Microglial Activation,” GLIA 29, 305-315 (2000).
Twining et al., “Spinal Fractalkine Induces Allodynia & Hyperalgesia,” Society for Neuroscience 27, 732, Abstract No. 279.12 (2001).
Watkins et al., “Spinal Fractalkine: Key Player in Exaggerated Pain States,” IASP Abstract No. 390-P24 (2002).
Verge et al., “Mapping Fractalkine and its Receptor (CX3CR1) in a Rat Model of Inflammatory Neuropathy,” IASP Abstract No. 393-P27 (2002).
Volin et al., “Fractalkine: A Novel Angiogenic Chemokine in Rheumatoid Arthritis,” Am. J. Pathology 159, 1521-1530 (2001).
Ruth et al., “Fractalkine, a Novel Chemokine in Rheumatoid Arthritis and in Rat Adjuvant-Induced Arthritis,” Arthritis Rheum. 44, 1568-1581 (2001).
Soriano et al., “Mice Deficient in Fractalkine are less Susceptible to Cerebral Ischemia-Reperfusion Injury,” J. Neuroimmunol. 125, 59-65 (2002).
Tarozzo et al., “Expression of Fractalkine and its Receptor, CX3CR1, in Response to Ischaemia-Reperfusion Brain Injury in the Rat,” Eur. J. Neuroscience 15, 1663-1668 (2002).
Chapman et al., “Fractalkine Cleavage from Neuronal Membranes Represents an Acute Event in the Inflammatory Response to Excitotoxic Brain Damage,” J. Neuroscience 20, 1-5 (2000).
Umehara et al., “Fractalkine and Vascular Injury,” Trends Immunol. 22, 602-607 (2001).
Moatti et al., “Polymorphism in the Fractalkine Receptor CX3CR1 as a Genetic Risk Factor for Coronary Artery Disease,” Blood 97, 1925-1928 (2001).
Balabanian et al., “CX3C Chemokine Fractalkine in Pulmonary Arterial Hypertension,” Am. J. Respir. Crit. Care Med. 165, 1419-1425 (2002).
Hanson Sverker
Nordvall Gunnar
AstraZeneca AB
Kondrad Karen H.
McKenzie Thomas C.
LandOfFree
Thiazolopyrimidine derivatives and use thereof as... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Thiazolopyrimidine derivatives and use thereof as..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Thiazolopyrimidine derivatives and use thereof as... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3648731